Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
Public ClinicalTrials.gov record NCT00723255. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving bevacizumab together with temsirolimus may kill more tumor cells.
Study identification
- NCT ID
- NCT00723255
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2008
- Primary completion
- Jul 14, 2011
- Completion
- Jan 24, 2016
- Last update posted
- Jul 22, 2019
2008 – 2016
United States locations
- U.S. sites
- 41
- U.S. states
- 18
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hartford Hospital | Hartford | Connecticut | 06102 | — |
| The Hospital of Central Connecticut | New Britain | Connecticut | 06050 | — |
| Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| Memorial University Medical Center | Savannah | Georgia | 31404 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Sudarshan K Sharma MD Limted-Gynecologic Oncology | Hinsdale | Illinois | 60521 | — |
| Elkhart General Hospital | Elkhart | Indiana | 46515 | — |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | — |
| Saint Vincent Hospital and Health Services | Indianapolis | Indiana | 46260 | — |
| Community Howard Regional Health | Kokomo | Indiana | 46904 | — |
| IU Health La Porte Hospital | La Porte | Indiana | 46350 | — |
| Saint Joseph Regional Medical Center-Mishawaka | Mishawaka | Indiana | 46545-1470 | — |
| Memorial Hospital of South Bend | South Bend | Indiana | 46601 | — |
| South Bend Clinic | South Bend | Indiana | 46617 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46628 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Gynecologic Oncology of West Michigan PLLC | Grand Rapids | Michigan | 49546 | — |
| Lakeland Hospital | Saint Joseph | Michigan | 49085 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Centerpoint Medical Center LLC | Independence | Missouri | 64057 | — |
| Truman Medical Center | Kansas City | Missouri | 64108 | — |
| Mercy Hospital Springfield | Springfield | Missouri | 65804 | — |
| Ozark Health Ventures LLC-Cancer Research for The Ozarks Springfield | Springfield | Missouri | 65804 | — |
| Saint Louis University Hospital | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Cooper Hospital University Medical Center | Camden | New Jersey | 08103 | — |
| Women's Cancer Care Associates LLC | Albany | New York | 12208 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Gynecologic Oncology Network | Greenville | North Carolina | 27834 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| MetroHealth Medical Center | Cleveland | Ohio | 44109 | — |
| Riverside Methodist Hospital | Columbus | Ohio | 43214 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Tulsa Cancer Institute | Tulsa | Oklahoma | 74146 | — |
| Abington Memorial Hospital | Abington | Pennsylvania | 19001 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Women and Infants Hospital | Providence | Rhode Island | 02905 | — |
| AnMed Health Cancer Center | Anderson | South Carolina | 29621 | — |
| Carilion Clinic Gynecological Oncology | Roanoke | Virginia | 24016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00723255, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2019 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00723255 live on ClinicalTrials.gov.